A5047939331- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Eosinophilic Disorders and Syndromes
- Chronic Lymphocytic Leukemia Research
- Kruppel-like factors research
- Childhood Cancer Survivors' Quality of Life
- Neutropenia and Cancer Infections
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- RNA Research and Splicing
- Histone Deacetylase Inhibitors Research
- RNA modifications and cancer
- CAR-T cell therapy research
- Fibroblast Growth Factor Research
- Protein Degradation and Inhibitors
- Palliative Care and End-of-Life Issues
- Frailty in Older Adults
- Lymphoma Diagnosis and Treatment
- Cancer survivorship and care
- Retinoids in leukemia and cellular processes
- Cytokine Signaling Pathways and Interactions
- COVID-19 and healthcare impacts
- Sepsis Diagnosis and Treatment
Dana-Farber Cancer Institute
2015-2024
Dana-Farber Brigham Cancer Center
2003-2024
AbbVie (United States)
2024
Blueprint Medicines (United States)
2024
Incyte (United States)
2024
Protagonist Therapeutics (United States)
2024
Merck (Singapore)
2024
Cogent Biosciences (United States)
2024
Bristol-Myers Squibb (Germany)
2024
Cogent (United Kingdom)
2024
The JAK2V617F allele has recently been identified in patients with polycythemia vera (PV), essential thrombocytosis (ET), and myelofibrosis myeloid metaplasia (MF). Subsequent analysis shown that constitutive activation of the JAK-STAT signal transduction pathway is an important pathogenetic event these patients, enzymatic inhibition may be therapeutic benefit this context. However, a significant proportion ET or MF are JAK2V617F-negative. We hypothesized might also occur as consequence...
Thrombosis in myeloproliferative neoplasms is associated with increased NETosis that can be targeted JAK inhibitors.
Abstract BACKGROUND. Few objective data exist on the burden of fatigue and other constitutional symptoms in patients with myeloproliferative disorders (MPD). METHODS. The authors used validated instruments physical activity assessment during an Internet‐based symptom survey 1179 MPD (median age, 56 years; 41.4% men). RESULTS. frequency self‐reporting was 80.7% for fatigue, which substantially higher than that pruritus (52.2%), night sweats (49.2%), bone pain (43.9%), fever (13.7%), weight...
The prognosis for adults with precursor B-cell acute lymphoblastic leukemia (B-ALL) remains poor, in part from a lack of therapeutic targets. We identified the type I cytokine receptor subunit CRLF2 functional screen B-ALL-derived mRNA transcripts that can substitute IL3 signaling. demonstrate is overexpressed approximately 15% adult and high-risk pediatric B-ALL MLL, TCF3, TEL, BCR/ABL rearrangements, but not these rearrangements or other lymphoid malignancies. overexpression result...
In a multi-institutional collaborative project, 1473 patients with myeloproliferative neoplasms (MPN) were screened for isocitrate dehydrogenase 1 (IDH1)/IDH2 mutations: 594 essential thrombocythemia (ET), 421 polycythemia vera (PV), 312 primary myelofibrosis (PMF), 95 post-PV/ET MF and 51 blast-phase MPN. A total of 38 IDH mutations (18 IDH1-R132, 19 IDH2-R140 IDH2-R172) detected: 5 (0.8%) ET, 8 (1.9%) PV, 13 (4.2%) PMF, (1%) 11 (21.6%) MPN (P<0.01). Mutant was documented in the presence or...
On the basis of data suggesting that adolescents and young adult patients with acute lymphoblastic leukemia (ALL) have improved outcomes when treated on pediatric protocols, we assessed feasibility treating aged 18–50 years ALL DFCI Pediatric Consortium regimen utilizing a 30-week course pharmacokinetically dose-adjusted E. coli L-asparaginase during consolidation. Between 2002 2008, 92 eligible were enrolled at 13 participating centers. Seventy-eight (85%) achieved complete remission (CR)...
Adults with relapsed/refractory acute lymphoblastic leukemia have an unfavourable prognosis, which is influenced by disease and patient characteristics. To further evaluate these characteristics, a retrospective analysis of 1,706 adult patients Ph-negative B-precursor diagnosed between 1990-2013 was conducted using data reflecting the standard care from 11 study groups large centers in Europe United States. Outcomes included complete remission, overall survival, realization stem cell...
Some cancers originate from a single mutation event in cell. Blood known as myeloproliferative neoplasms (MPNs) are thought to when driver is acquired by hematopoietic stem cell (HSC). However, the first occurs individuals and how it affects behavior of HSCs their native context not known. Here we quantified effect JAK2-V617F on self-renewal differentiation dynamics treatment-naive with MPNs reconstructed lineage histories individual using somatic patterns. We found that mutations occurred...
The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN) consist of myelofibrosis, polycythemia vera, and essential thrombocythemia are a heterogeneous group clonal blood disorders characterized by an overproduction cells. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as result meetings convened multidisciplinary panel with expertise MPN, the goal providing recommendations management adults. include diagnostic workup, risk...
Clinical correlates and long-term prognostic relevance of the JAK2(V617F) mutation was studied in 150 patients with essential thrombocythaemia (ET) from a single institution followed for median 11.4 years. During this period, thrombotic complications were documented 62 (41.3%) transformation into acute myeloid leukaemia (AML), polycythaemia vera (PV), or myelofibrosis metaplasia (MMM) occurred 4 (2.7%), 8 (5.3%), 15 (10%) patients, respectively. detected either archived bone marrow blood...
Several studies have recently reported on the occurrence of a JAK2(V617F) mutation in myeloid cells from majority patients with polycythemia vera (PV). The clinical relevance this novel observation currently is under study.In single institutional study, screening for was performed DNA derived archived blood granulocytes 63 consecutive PV whom current diagnostic criteria were strictly applied and diagnosis confirmed by bone marrow histology.The mutant allele detected 58 (92%) 21%...
An association between an activating JAK2 mutation (JAK2(V617F)) and BCR/ABL-negative myeloproliferative disorders was recently reported in multiple simultaneous publications. In the current study, analysis for JAK2(V617F) performed peripheral blood mononuclear cells (PBMC) from 157 patients with myelofibrosis myeloid metaplasia (MMM) including 117 agnogenic (AMM), 22 postpolycythaemic (PPMM), 18 post-thrombocythaemic (PTMM) metaplasia. The detection rate significantly higher PPMM (91%;...